Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases

Blood

Volumn 95, Issue 9, 2000, Pages 2913-2921

  Quackenbush, Robert C ^b   Reuther, Gary W ^b   Miller, Juli P ^b   Courtney, Kevin D ^b   Pear, Warren S ^b   Pendergast, Ann Marie ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; GENE TRANSFER; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMOGENESIS; MOLECULAR CLONING; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 0034192222     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.9.2913.009k32_2913_2921     Document Type: Article

References (47)

1. Melo J. The diversity of Bcr-Abl fusion proteins and their relationship to leukemia phenotype Blood. 1996;88:2375.
2. Pendergast A, Quilliam LA, Cripe LD, et al. Bcr-Abl induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175.
3. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for Bcr-Abl-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 1995;15:5531.
4. Salomoni P, Wasik MA, Riedel RF, et al. Expression of contitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient Bcr/Abl mutant, J Exp Med. 1998;187:1995.
5. Okuka K, Matulonis U, Salgia R, Kanakura Y, Druker B, Griffin JD. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol. 1994;22:1111.
6. Cortez D, Reuther G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 1997;15: 2333.
7. Burgess G, Williamson EA, Cripe LD, et al. Regulation of the c-jun gene in P210 Bcr-Abl transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase. Blood. 1998;92:2450.
8. Sawyers C, Callahan W, Witte ON. Dominant negative MYC blocks transformation by Abl oncogenes. Cell. 1992;70:901.
9. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the Bcr-Abl oncogene in chronic myelogenous leukemia. Oncogene. 1996;13:247.
10. Ilaria R Jr, VanEtten RA. P210 and P190(Bcr/Abl) induce the tryosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271:31,704.
11. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by Bcr/Abl requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 1997;16:6151.
12. Reuther J, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. Activation of NF-kB is required for Bcr-Abl-mediated tumorigenesis. Genes Dev. 1998;12:968.
13. Dai Z, Quackenbush RC, Courtney KD, et al. Oncogenic Abl and Src tryosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev. 1998;12:1415.
14. Kurzrock R, Shtalrid M, Romero P, et al. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature. 1987; 325:631.
15. Chan L, Karhi KK, Rayter SI, et al. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature. 1987;325:635.
16. Preti H, O'Brien S, Giralt S, Beran M, Pierce S, Kantarjian HM. Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med. 1994;97:60.
17. Shepherd P Jr, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenic response, duration of chronic phase, or survival. Br J Haematol. 1995;89:546.
18. Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (Bcr/Abl with C3/A2 junction). Blood. 1996;88:2410.
19. Saglio G, Guerrasio A, Rosso C, et al. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1990;76:1819.
20. Wilson G, Frost L, Goodeye A, Vandenberghe E, Peake I, Reilly J. Bcr-Abl transcript with an e19a2 (c3a2) junction in classical chronic myelogenous leukemia [letter]. Blood. 197;89:3064.
21. Mirtre H, Leymarie P, Macro M, Leporrier M. A new case of chronic myeloid leukemia with c3/a2 BCR/ABL junction: is it really a distinct disease? [letter]. Blood. 1997;89:4239.
22. Briz M, Vilches C, Cabrera R, Fores R, Fernandez MN. Typical chronic myelogenous leukemia with e19a2 junction BCR/ABL transcript [letter]. Blood. 1997;90:5024.
23. Pendergast A, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transformation by the Bcr-Abl oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 1991;66:161.
24. Muller A, Young JC, Pendergast AM, et al. BCR first exon sequences specifically activate the Bcr/ Abl tryosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol. 1991;11:1785.
25. Pear W, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA. 1993;90:8392.
26. Persons D, Allay JA, Allay ER, et al. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood. 1997;90:1777.
27. Pear W, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/ abl-transduced bone marrow. Blood. 1998;92:3780.
28. Pendergast A, Gishizky ML, Havlik MH, Witte ON. SH1 domain autophosphorylation of P210 Bcr/ Abl is required for transformation but not growth factor independence. Mol Cell Biol. 1993;13:1728.
29. Raitano A, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A. 1995;92:11,746.
30. Young J, Witte ON. Selective transformation of primative lymphoid cells by the Bcr/Abl oncogene expressed in lymphoid or myeloid cultures. Mol Cell Biol. 1988;8:4079.
31. Leslie N, O'Prey J, Bartholomew C, Harrison PR. An activating mutation in the kit receptor abolishes the stroma requirement for growth of ELM erythroleukemia cells, but does not prevent their differentiation in response to erythropoietin. Blood. 1998;92:4798.
32. Ferrero D, Carlesso N, Gallo E, Pregno P, De-Fabritiis P, Petti MC, Mandelli F. CD9 antigen on acute non-lymphoid leukemia cells: preferential expression by promyelocytic (M3) subtype. Leuk Res. 1991;15:457.
33. Erber W, Asbahr H, Rule SA, Scott CS. Unique immunophenotype of acute promyelocytic leukaemia as defined by CD9 and CD68 antibodies. Br J Haematol. 1994;88:101.
34. Guglielmi C, Martelli MP, Diverio D, et al. Immunophenotype of adult and childhood acute promyelocytic leukemia: correlation with morphology, type of PML gene breakpoint and clinical outcome: a cooperative Italian study on 196 cases. Br J Haematol. 1998;102:1035.
35. Oritani K, Wu X, Medina K, et al. Antibody ligation of CD9 modifies production of myeloid cells in long-term cultures. Blood. 1996;87:2252.
36. DiNoto R, LoRardo C, Schiavone EM, et al. Stem cell factor receptor (cKit, CD117) is expressed on blast cells from most immature types of acute myeloid malignancies but is also a characteristic of a subset of acute promyelocytic leukemia. Br J Haematol. 1996;92:562.
37. Nomdedeu J, Mateu R, Altes A, et al. Enhanced myeloid specificity of CD117 compared with CD13 and CD 33. Leuk Res. 1999;23:341.
38. Bene M, Bernier M, Casasnovas RO, et al. The reliability and specificity of cKit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. Blood. 1998;92:596.
39. Douer D, Levin AM, Sparkes RS, et al. Chronic myelocytic leukemia: a pluripotent haemopoietic cell is involved in the malignant clone. Br J Haematol. 1981;49:615.
40. Fialkow P, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977;63:125.
41. Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA. The P190, P210 and P230 forms of the Bcr/ Abl oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189:1399.
42. Tachibana N, Raimondi SC, Lauer SJ, Sartain P, Dow LW. Evidence for a multipotential slem cell disease in some childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1987;70:1458.
43. Dow L, Tachibana N, Raimondi SC, Lauer SJ, Witte ON, Clark SS. Comparative biochemical and cytogenetic studies of childhood acute lymphoblastic leukemia with the Philadelphia chromosome and other 22q11 variants. Blood. 1989; 73:1291.
44. Schenk T, Keyhani A, Bottcher S, et al. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia. 1998;12:666.
45. Skorski T, Wlodarski P, Daheron L, et al. Bcr/Abl-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc Natl Acad Sci U S A. 1998;95:11,858.
46. Ponting C, Parker PJ. Extending the C2 domain family: C2s in PKCs δb ∈b ηb θb phospholipases, GAPs, and perforin. Protein Sci. 1996;5:162.
47. Gross AW, Zhang X, Ren R. Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol Cell Biol 1999;19:6918.